Clinical Trials Directory

Trials / Terminated

TerminatedNCT03270709

Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV

Effect of High-Dose Vitamin D3 on Alveolar Macrophage Function, LL-37, and Oxidative Stress in Smokers and Non-Smokers With and Without HIV

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
7 (actual)
Sponsor
Emory University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Supplementation with vitamin D improves HIV+ macrophages phagocytosis in vitro. There is evidence to suggest that administering vitamin D can in fact improve immune function in individuals. The study will evaluate the impact of high dose vitamin D in HIV+ smokers' and HIV- smokers' in vivo. The primary goal is to improve innate immune host response to infection in patients already at high risk by virtue of HIV and smoking status.

Detailed description

Tobacco smoke suppresses the lung's ability to fight infection. Smoking is three times more prevalent in the HIV+ compared to HIV- patients. Viral load was found to be significantly increased in HIV+ smokers compared to HIV+ non-smokers, suggesting that smoking enhances HIV-1 viral replication in macrophages, which contributes to disease progression. Vitamin D deficiency has been associated with increased mortality in HIV+ persons, but there is limited research on how this is impacting the health of these highest risk patients and if aggressive repletion with vitamin D can improve overall health.The study team hypothesizes that vitamin D administration will increase pathogen clearance and improve innate immune function. The proposed pre and post interventional study is designed to characterize alveolar macrophage function and lung immunity according to tobacco use and HIV status, and determine the impact of high dose oral vitamin D3 on AM phagocytic function and innate immunity.

Conditions

Interventions

TypeNameDescription
DRUGVitamin D3 450,000 IU orallyStudy subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.

Timeline

Start date
2018-04-11
Primary completion
2018-10-15
Completion
2018-10-15
First posted
2017-09-01
Last updated
2021-04-21

Locations

2 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT03270709. Inclusion in this directory is not an endorsement.